miRNA Details
miRNA General Information | |||||
---|---|---|---|---|---|
miRNA Mature ID | hsa-miR-145-5p | ||||
miRNA Stemloop AC | MI0000461 | ||||
miRNA Stemloop ID | hsa-mir-145 | ||||
Sequence | guccaguuuucccaggaaucccu | ||||
TTD Target(s) Regulated by This miRNA | Epidermal growth factor receptor (EGFR) | Successful Target | Target Info | [1] | |
Estrogen receptor (ESR) | Successful Target | Target Info | [2] | ||
Matrix metalloproteinase-1 (MMP-1) | Successful Target | Target Info | [3] | ||
Serine/threonine-protein kinase B-raf (BRAF) | Successful Target | Target Info | [4] | ||
Aromatic-L-amino-acid decarboxylase (DDC) | Successful Target | Target Info | [5] | ||
Calcineurin (PPP3CA) | Successful Target | Target Info | [6] | ||
Cyclin-dependent kinase 4 (CDK4) | Successful Target | Target Info | [7] | ||
Cyclin-dependent kinase 6 (CDK6) | Successful Target | Target Info | [8] | ||
Insulin-like growth factor I receptor (IGF1R) | Successful Target | Target Info | [9] | ||
Multidrug resistance-associated protein 1 (ABCC1) | Successful Target | Target Info | [10] | ||
cAMP-dependent chloride channel (CFTR) | Successful Target | Target Info | [11] | ||
Interferon-beta (IFNB1) | Successful Target | Target Info | [12] | ||
Vascular endothelial growth factor A (VEGFA) | Successful Target | Target Info | [13] | ||
T-cell-specific surface glycoprotein CD28 (CD28) | Successful Target | Target Info | [14] | ||
Mothers against decapentaplegic homolog 3 (SMAD3) | Successful Target | Target Info | [15] | ||
Rho-associated protein kinase 1 (ROCK1) | Successful Target | Target Info | [16] | ||
Histone deacetylase 2 (HDAC2) | Clinical trial Target | Target Info | [17] | ||
TNF alpha converting enzyme (ADAM17) | Clinical trial Target | Target Info | [18] | ||
Matrix metalloproteinase-12 (MMP-12) | Clinical trial Target | Target Info | [3] | ||
Matrix metalloproteinase-14 (MMP-14) | Clinical trial Target | Target Info | [3] | ||
Ribosomal protein S6 kinase beta-1 (S6K1) | Clinical trial Target | Target Info | [19] | ||
Ubiquitin-protein ligase E3 Mdm2 (MDM2) | Clinical trial Target | Target Info | [20] | ||
Yes tyrosine kinase (YES) | Clinical trial Target | Target Info | [21] | ||
Angiopoietin-2 (ANGPT2) | Successful Target | Target Info | [22] | ||
CD40L receptor (CD40) | Clinical trial Target | Target Info | [23] | ||
Endothelial plasminogen activator inhibitor (SERPINE1) | Clinical trial Target | Target Info | [24] | ||
Transforming growth factor beta 2 (TGFB2) | Clinical trial Target | Target Info | [25] | ||
GTPase NRas (NRAS) | Clinical trial Target | Target Info | [13] | ||
PAK-4 protein kinase (PAK4) | Clinical trial Target | Target Info | [26] | ||
TGF-beta receptor type II (TGFBR2) | Clinical trial Target | Target Info | [27] | ||
A proliferation-inducing ligand (APRIL) | Clinical trial Target | Target Info | [28] | ||
Connective tissue growth factor (CTGF) | Clinical trial Target | Target Info | [29] | ||
Frizzled-7 receptor (FZD7) | Clinical trial Target | Target Info | [30] | ||
Hypoxia-inducible factor 1 alpha (HIF-1A) | Clinical trial Target | Target Info | [31] | ||
Mucin-1 (MUC1) | Clinical trial Target | Target Info | [32] | ||
Neural cadherin (CDH2) | Clinical trial Target | Target Info | [33] | ||
Extracellular matrix receptor III (CD44) | Clinical trial Target | Target Info | [4] | ||
Hypoxia-inducible factor 2 alpha (HIF-2A) | Successful Target | Target Info | [34] | ||
Spectrin non-erythroid beta chain 1 (SPTBN1) | Clinical trial Target | Target Info | [35] | ||
Fascin (FSCN1) | Clinical trial Target | Target Info | [36] | ||
Kruppel like factor 4 (KLF4) | Clinical trial Target | Target Info | [37] | ||
Transcription factor Sp1 (SP1) | Clinical trial Target | Target Info | [8] | ||
Signal transducer and activator of transcription 1 (STAT1) | Patented-recorded Target | Target Info | [21] | ||
Histone deacetylase 11 (HDAC11) | Patented-recorded Target | Target Info | [38] | ||
Toll/interleukin-1 receptor domain-containing adapter (TIRAP) | Patented-recorded Target | Target Info | [39] | ||
Integrin-linked protein kinase 1 (ILK) | Patented-recorded Target | Target Info | [40] | ||
Proto-oncogene c-Myc (MYC) | Literature-reported Target | Target Info | [41] | ||
Protein tyrosine phosphatase IVA 2 (PRL-2) | Literature-reported Target | Target Info | [3] | ||
Sentrin specific protease-1 (SENP1) | Literature-reported Target | Target Info | [42] | ||
Alkaline phosphatase (ALPPL2) | Literature-reported Target | Target Info | [3] | ||
Integrin beta-8 (ITGB8) | Clinical trial Target | Target Info | [43] | ||
Junctional adhesion molecule A (F11R) | Literature-reported Target | Target Info | [44] | ||
Protein C-ets-1 (ETS1) | Literature-reported Target | Target Info | [45] | ||
Protein phosphatase 1D (PPM1D) | Literature-reported Target | Target Info | [46] | ||
DNA fragmentation factor alpha (DFFA) | Literature-reported Target | Target Info | [47] | ||
Enhancer of filamentation 1 (NEDD9) | Literature-reported Target | Target Info | [48] | ||
Eukaryotic initiation factor 4E (EIF4E) | Literature-reported Target | Target Info | [7] | ||
Insulin receptor substrate-1 (IRS1) | Clinical trial Target | Target Info | [49] | ||
Melanoma differentiation-associated protein 6 (CDKN1A) | Literature-reported Target | Target Info | [50] | ||
Metastasis adhesion protein (MTDH) | Literature-reported Target | Target Info | [51] | ||
Transcription factor SOX-2 (SOX2) | Literature-reported Target | Target Info | [24] | ||
High mobility group protein HMGI-C (HMGA2) | Literature-reported Target | Target Info | [52] | ||
Protein(s) Regulated by This miRNA | 7,8-dihydro-8-oxoguanine triphosphatase | Regulated Protein | [1] | ||
Actin, cytoplasmic 1 | Regulated Protein | [54] | |||
Acyl-protein thioesterase 2 | Regulated Protein | [3] | |||
ADP-ribosylation factor 6 | Regulated Protein | [56] | |||
Aldehyde dehydrogenase, dimeric NADP-preferring | Regulated Protein | [3] | |||
Aldo-keto reductase family 1 member B10 | Regulated Protein | [3] | |||
Alpha/beta hydrolase domain-containing protein 17C | Regulated Protein | [3] | |||
AP-1 complex subunit gamma-1 | Regulated Protein | [3] | |||
Baculoviral IAP repeat-containing protein 1 | Regulated Protein | [57] | |||
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 | Regulated Protein | [58] | |||
Beta/gamma crystallin domain-containing protein 1 | Regulated Protein | [59] | |||
Calcium/calmodulin-dependent protein kinase type 1D | Regulated Protein | [60] | |||
Catenin delta-1 | Regulated Protein | [61] | |||
Centrosomal protein of 19 kDa | Regulated Protein | [3] | |||
Clathrin interactor 1 | Regulated Protein | [6] | |||
Coiled-coil domain-containing protein 43 | Regulated Protein | [3] | |||
Collagen alpha-1(V) chain | Regulated Protein | [63] | |||
Core-binding factor subunit beta | Regulated Protein | [6] | |||
Costars family protein ABRACL | Regulated Protein | [3] | |||
Cytochrome c oxidase subunit NDUFA4 | Regulated Protein | [3] | |||
Cytoplasmic polyadenylation element-binding protein 4 | Regulated Protein | [30] | |||
D-aminoacyl-tRNA deacylase 1 | Regulated Protein | [3] | |||
DNA mismatch repair protein Msh3 | Regulated Protein | [65] | |||
DNA replication licensing factor MCM2 | Regulated Protein | [35] | |||
Dual specificity mitogen-activated protein kinase kinase 6 | Regulated Protein | [3] | |||
Frataxin, mitochondrial | Regulated Protein | [67] | |||
Friend leukemia integration 1 transcription factor | Regulated Protein | [68] | |||
Gamma-adducin | Regulated Protein | [69] | |||
Glia maturation factor beta | Regulated Protein | [3] | |||
Golgi membrane protein 1 | Regulated Protein | [3] | |||
Helicase-like transcription factor | Regulated Protein | [3] | |||
Homeobox protein Hox-A9 | Regulated Protein | [70] | |||
Homeobox protein MIXL1 | Regulated Protein | [3] | |||
Homeobox protein NANOG | Regulated Protein | [71] | |||
Insulin receptor substrate 2 | Regulated Protein | [72] | |||
Keratin, type II cytoskeletal 7 | Regulated Protein | [73] | |||
Kinesin-like protein KIF21A | Regulated Protein | [59] | |||
Kremen protein 1 | Regulated Protein | [3] | |||
Krueppel-like factor 5 | Regulated Protein | [4] | |||
Mesoderm-specific transcript homolog protein | Regulated Protein | [3] | |||
Mothers against decapentaplegic homolog 2 | Regulated Protein | [25] | |||
Myelin regulatory factor | Regulated Protein | [30] | |||
Myocardin | Regulated Protein | [76] | |||
Myotubularin-related protein 14 | Regulated Protein | [3] | |||
Nuclear factor of activated T-cells, cytoplasmic 1 | Regulated Protein | [14] | |||
Paxillin | Regulated Protein | [78] | |||
Phosphatase and actin regulator 2 | Regulated Protein | [59] | |||
Phosphatidylinositol-glycan biosynthesis class F protein | Regulated Protein | [3] | |||
Podocalyxin | Regulated Protein | [3] | |||
POU domain, class 5, transcription factor 1 | Regulated Protein | [37] | |||
PRA1 family protein 3 | Regulated Protein | [3] | |||
Probable ATP-dependent RNA helicase DDX17 | Regulated Protein | [80] | |||
Probable ATP-dependent RNA helicase DDX6 | Regulated Protein | [81] | |||
Protein FAM3C | Regulated Protein | [3] | |||
Protein FAM45A | Regulated Protein | [3] | |||
Protein Jade-1 | Regulated Protein | [3] | |||
Protein jagged-1 | Regulated Protein | [82] | |||
Protein mono-ADP-ribosyltransferase PARP8 | Regulated Protein | [83] | |||
Protein NDRG2 | Regulated Protein | [3] | |||
Protein NipSnap homolog 1 | Regulated Protein | [3] | |||
Protein SET | Regulated Protein | [35] | |||
Protein-arginine deiminase type-1 | Regulated Protein | [59] | |||
Ras-responsive element-binding protein 1 | Regulated Protein | [84] | |||
Replication protein A 70 kDa DNA-binding subunit | Regulated Protein | [35] | |||
Rhotekin | Regulated Protein | [85] | |||
Roundabout homolog 2 | Regulated Protein | [86] | |||
Serine incorporator 5 | Regulated Protein | [3] | |||
Serine palmitoyltransferase 1 | Regulated Protein | [35] | |||
SLIT-ROBO Rho GTPase-activating protein 1 | Regulated Protein | [86] | |||
Sorting nexin-24 | Regulated Protein | [59] | |||
Sterile alpha motif domain-containing protein 5 | Regulated Protein | [59] | |||
Suppressor of cytokine signaling 7 | Regulated Protein | [87] | |||
Switch-associated protein 70 | Regulated Protein | [88] | |||
Tetraspanin-6 | Regulated Protein | [3] | |||
Transcription factor SOX-9 | Regulated Protein | [69] | |||
Transcription factor Sp7 | Regulated Protein | [89] | |||
Transcriptional regulator ERG | Regulated Protein | [90] | |||
Transmembrane protein 9B | Regulated Protein | [3] | |||
Tropomodulin-3 | Regulated Protein | [83] | |||
Tropomyosin alpha-3 chain | Regulated Protein | [3] | |||
Tumor protein p63-regulated gene 1 protein | Regulated Protein | [3] | |||
Uncharacterized protein C11orf65 | Regulated Protein | [3] | |||
Unconventional myosin-Va | Regulated Protein | [91] | |||
Unconventional myosin-VI | Regulated Protein | [92] | |||
Vacuolar protein sorting-associated protein 51 homolog | Regulated Protein | [93] | |||
References | |||||
REF 1 | MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol. 2011 Jan-Feb;8(1):125-31. | ||||
REF 2 | miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ. 2010 Feb;17(2):246-54. | ||||
REF 3 | miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer. 2010 Dec 15;127(12):2804-14. | ||||
REF 4 | Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene. 2013 Oct;32(40):4806-13. | ||||
REF 5 | Human L-DOPA decarboxylase mRNA is a target of miR-145: A prediction to validation workflow. Gene. 2015 Jan 10;554(2):174-80. | ||||
REF 6 | miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene. 2010 Feb 18;29(7):1073-84. | ||||
REF 7 | miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Cancer Res. 2010 Nov 22;29:151. | ||||
REF 8 | miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6. Int J Cancer. 2014 Sep 15;135(6):1286-96. | ||||
REF 9 | Mechanism of growth inhibition by MicroRNA 145: the role of the IGF-I receptor signaling pathway. J Cell Physiol. 2009 Aug;220(2):485-91. | ||||
REF 10 | Direct conversion of fibroblasts to neurons by reprogramming PTB-regulated microRNA circuits. Cell. 2013 Jan 17;152(1-2):82-96. | ||||
REF 11 | Regulation of cystic fibrosis transmembrane conductance regulator by microRNA-145, -223, and -494 is altered in F508 cystic fibrosis airway epithelium. J Immunol. 2013 Apr 1;190(7):3354-62. | ||||
REF 12 | MicroRNA regulation of IFN-beta protein expression: rapid and sensitive modulation of the innate immune response. J Immunol. 2010 Mar 1;184(5):2369-76. | ||||
REF 13 | MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF. Cell Cycle. 2012 Jun 1;11(11):2137-45. | ||||
REF 14 | Identification of novel MicroRNA signatures linked to experimental autoimmune myasthenia gravis pathogenesis: down-regulated miR-145 promotes pathogenetic Th17 cell response. J Neuroimmune Pharmacol. 2013 Dec;8(5):1287-302. | ||||
REF 15 | Elevated levels of miR-145 correlate with SMAD3 down-regulation in cystic fibrosis patients. J Cyst Fibros. 2013 Dec;12(6):797-802. | ||||
REF 16 | ROCK1, a novel target of miR-145, promotes glioma cell invasion. Mol Med Rep. 2014 May;9(5):1877-82. | ||||
REF 17 | MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer. Cancer Lett. 2013 Jul 28;335(2):455-62. | ||||
REF 18 | MiR-145 reduces ADAM17 expression and inhibits in vitro migration and invasion of glioma cells. Oncol Rep. 2013 Jan;29(1):67-72. | ||||
REF 19 | MiR-145 is downregulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1. Biochem Biophys Res Commun. 2013 Nov 29;441(4):693-700. | ||||
REF 20 | Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop. Oncogene. 2013 Jan 3;32(1):61-9. | ||||
REF 21 | MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS One. 2010 Jan 21;5(1):e8836. | ||||
REF 22 | miR-145 functions as tumor suppressor and targets two oncogenes, ANGPT2 and NEDD9, in renal cell carcinoma. J Cancer Res Clin Oncol. 2014 Mar;140(3):387-97. | ||||
REF 23 | miRNA-145 inhibits VSMC proliferation by targeting CD40. Sci Rep. 2016 Oct 12;6:35302. | ||||
REF 24 | MicroRNA miR-145 inhibits proliferation, invasiveness, and stem cell phenotype of an initro endometriosis model by targeting multiple cytoskeletal elements and pluripotency factors. Fertil Steril. 2013 Apr;99(5):1346-1355.e5. | ||||
REF 25 | Umbilical Cord-Derived Mesenchymal Stem Cell-Derived Exosomal MicroRNAs Suppress Myofibroblast Differentiation by Inhibiting the Transforming Growth Factor-/SMAD2 Pathway During Wound Healing. Stem Cells Transl Med. 2016 Oct;5(10):1425-1439. | ||||
REF 26 | MiR-145 regulates PAK4 via the MAPK pathway and exhibits an antitumor effect in human colon cells. Biochem Biophys Res Commun. 2012 Oct 26;427(3):444-9. | ||||
REF 27 | Expression patterns and regulatory functions of microRNAs during the initiation of primordial follicle development in the neonatal mouse ovary. Biol Reprod. 2013 Nov 27;89(5):126. | ||||
REF 28 | APRIL induces cisplatin resistance in gastric cancer cells via activation of the NF-B pathway. Cell Physiol Biochem. 2015;35(2):571-85. | ||||
REF 29 | MicroRNA-145 is downregulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor. PLoS One. 2013;8(2):e54652. | ||||
REF 30 | Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene. Cancer. 2011 Jan 1;117(1):86-95. | ||||
REF 31 | Identification of a hypoxia-regulated miRNA signature in bladder cancer and a role for miR-145 in hypoxia-dependent apoptosis. Br J Cancer. 2015 Aug 11;113(4):634-44. | ||||
REF 32 | MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res. 2010 Jan 1;70(1):378-87. | ||||
REF 33 | The molecular mechanism of microRNA-145 to suppress invasion-metastasis cascade in gastric cancer. Oncogene. 2013 Jan 24;32(4):491-501. | ||||
REF 34 | MicroRNA-145 inhibits the growth, invasion, metastasis and angiogenesis of neuroblastoma cells through targeting hypoxia-inducible factor 2 alpha. Oncogene. 2014 Jan 16;33(3):387-97. | ||||
REF 35 | Identification of miR-145 targets through an integrated omics analysis. Mol Biosyst. 2015 Jan;11(1):197-207. | ||||
REF 36 | miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer. 2010 Mar 2;102(5):883-91. | ||||
REF 37 | MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell. 2009 May 15;137(4):647-58. | ||||
REF 38 | Type I IFN inhibits innate IL-10 production in macrophages through histone deacetylase 11 by downregulating microRNA-145. J Immunol. 2013 Oct 1;191(7):3896-904. | ||||
REF 39 | Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med. 2010 Jan;16(1):49-58. | ||||
REF 40 | Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways. Cancer Lett. 2013 Jan 28;328(2):353-61. | ||||
REF 41 | Prediction and preliminary validation of oncogene regulation by miRNAs. BMC Mol Biol. 2007 Sep 18;8:79. | ||||
REF 42 | Tumor-suppressive microRNA-145 induces growth arrest by targeting SENP1 in human prostate cancer cells. Cancer Sci. 2015 Apr;106(4):375-82. | ||||
REF 43 | MicroRNA-145 regulates human corneal epithelial differentiation. PLoS One. 2011;6(6):e21249. | ||||
REF 44 | miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene. 2010 Dec 16;29(50):6569-80. | ||||
REF 45 | miRNA-145 targets v-ets erythroblastosis virus E26 oncogene homolog 1 to suppress the invasion, metastasis, and angiogenesis of gastric cancer cells. Mol Cancer Res. 2013 Feb;11(2):182-93. | ||||
REF 46 | Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway. Cancer Res. 2010 Sep 15;70(18):7176-86. | ||||
REF 47 | MiR-145, a new regulator of the DNA fragmentation factor-45 (DFF45)-mediated apoptotic network. Mol Cancer. 2010 Aug 6;9:211. | ||||
REF 48 | NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Oncotarget. 2012 Jul;3(7):723-34. | ||||
REF 49 | Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem. 2007 Nov 9;282(45):32582-90. | ||||
REF 50 | Screening key microRNAs for castration-resistant prostate cancer based on miRNA/mRNA functional synergistic network. Oncotarget. 2015 Dec 22;6(41):43819-30. | ||||
REF 51 | MiR-145 acts as a metastasis suppressor by targeting metadherin in lung cancer. Med Oncol. 2015 Jan;32(1):344. | ||||
REF 52 | miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma. Cancer Lett. 2015 Jan 28;356(2 Pt B):937-45. | ||||
REF 53 | MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol. 2011 Jan-Feb;8(1):125-31. | ||||
REF 54 | Decreased expression of microRNA-143 and -145 in human gastric cancers. Oncology. 2009;77(1):12-21. | ||||
REF 55 | miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer. 2010 Dec 15;127(12):2804-14. | ||||
REF 56 | lincRNA-RoR and miR-145 regulate invasion in triple-negative breast cancer via targeting ARF6.Mol Cancer Res. 2015 Feb;13(2):330-8. | ||||
REF 57 | Downregulation of microRNA-1 and microRNA-145 contributes synergistically to the development of colon cancer.Int J Mol Med. 2015 Dec;36(6):1630-8. | ||||
REF 58 | MicroRNA145 targets BNIP3 and suppresses prostate cancer progression.Cancer Res. 2010 Apr 1;70(7):2728-38. | ||||
REF 59 | MicroRNA profiling in mucosal biopsies of eosinophilic esophagitis patients pre and post treatment with steroids and relationship with mRNA targets. PLoS One. 2012;7(7):e40676. | ||||
REF 60 | Stromal Expression of miR-143/145 Promotes Neoangiogenesis in Lung Cancer Development.Cancer Discov. 2016 Feb;6(2):188-201. | ||||
REF 61 | Catenin-1, negatively regulated by miR-145, promotes tumour aggressiveness in gastric cancer.J Pathol. 2015 May;236(1):53-64. | ||||
REF 62 | miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene. 2010 Feb 18;29(7):1073-84. | ||||
REF 63 | miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells.Oncogene. 2013 Sep 26;32(39):4712-20. | ||||
REF 64 | Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene. Cancer. 2011 Jan 1;117(1):86-95. | ||||
REF 65 | miR-145 sensitizes gallbladder cancer to cisplatin by regulating multidrug resistance associated protein 1.Tumour Biol. 2016 Aug;37(8):10553-62. | ||||
REF 66 | Identification of miR-145 targets through an integrated omics analysis. Mol Biosyst. 2015 Jan;11(1):197-207. | ||||
REF 67 | MiRNA-145 Regulates the Development of Congenital Heart Disease Through Targeting FXN.Pediatr Cardiol. 2016 Apr;37(4):629-36. | ||||
REF 68 | EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells.Genes Dev. 2010 May;24(9):916-32. | ||||
REF 69 | MiR-145 functions as a tumor-suppressive RNA by targeting Sox9 and adducin 3 in human glioma cells.Neuro Oncol. 2013 Oct;15(10):1302-16. | ||||
REF 70 | MicroRNA-126 regulates HOXA9 by binding to the homeobox.Mol Cell Biol. 2008 Jul;28(14):4609-19. | ||||
REF 71 | Endogenous miRNA sponge lincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic stem cell self-renewal. Dev Cell. 2013 Apr 15;25(1):69-80. | ||||
REF 72 | MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma. Carcinogenesis. 2012 Jun;33(6):1134-41. | ||||
REF 73 | Identification of novel microRNA targets based on microRNA signatures in bladder cancer.Int J Cancer. 2009 Jul 15;125(2):345-52. | ||||
REF 74 | Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene. 2013 Oct;32(40):4806-13. | ||||
REF 75 | Umbilical Cord-Derived Mesenchymal Stem Cell-Derived Exosomal MicroRNAs Suppress Myofibroblast Differentiation by Inhibiting the Transforming Growth Factor-/SMAD2 Pathway During Wound Healing. Stem Cells Transl Med. 2016 Oct;5(10):1425-1439. | ||||
REF 76 | Angiotensin II Downregulates MicroRNA-145 to Regulate Kruppel-like Factor 4 and Myocardin Expression in Human Coronary Arterial Smooth Muscle Cells under High Glucose Conditions. Mol Med. 2015 Jul 14;21:616-25. | ||||
REF 77 | Identification of novel MicroRNA signatures linked to experimental autoimmune myasthenia gravis pathogenesis: down-regulated miR-145 promotes pathogenetic Th17 cell response. J Neuroimmune Pharmacol. 2013 Dec;8(5):1287-302. | ||||
REF 78 | MicroRNA-145 suppresses cell migration and invasion by targeting paxillin in human colorectal cancer cells. Int J Clin Exp Pathol. 2015 Feb 1;8(2):1328-40. | ||||
REF 79 | MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell. 2009 May 15;137(4):647-58. | ||||
REF 80 | Forced expression of miR-143 represses ERK5/c-Myc and p68/p72 signaling in concert with miR-145 in gut tumors of Apc(Min) mice.PLoS One. 2012;7(8):e42137. | ||||
REF 81 | DDX6 post-transcriptionally down-regulates miR-143/145 expression through host gene NCR143/145 in cancer cells.Biochim Biophys Acta. 2013 Oct;1829(10):1102-10. | ||||
REF 82 | The miR-143/145 cluster is a novel transcriptional target of Jagged-1/Notch signaling in vascular smooth muscle cells.J Biol Chem. 2011 Aug 12;286(32):28312-21. | ||||
REF 83 | A combined computational-experimental approach predicts human microRNA targets. Genes Dev. 2004 May 15;18(10):1165-78. | ||||
REF 84 | RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets.Oncogene. 2013 May 16;32(20):2576-85. | ||||
REF 85 | miR-145 inhibits breast cancer cell growth through RTKN.Int J Oncol. 2009 May;34(5):1461-6. | ||||
REF 86 | MicroRNAs 144, 145, and 214 are down-regulated in primary neurons responding to sciatic nerve transection.Brain Res. 2011 Apr 6;1383:62-70. | ||||
REF 87 | socs7, a target gene of microRNA-145, regulates interferon- induction through STAT3 nuclear translocation in bladder cancer cells.Cell Death Dis. 2013 Feb 7;4:e482. | ||||
REF 88 | SWAP70, actin-binding protein, function as an oncogene targeting tumor-suppressive miR-145 in prostate cancer.Prostate. 2011 Oct 1;71(14):1559-67. | ||||
REF 89 | miR-145 suppresses osteogenic differentiation by targeting Sp7.FEBS Lett. 2013 Sep 17;587(18):3027-31. | ||||
REF 90 | The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer.FEBS J. 2013 May;280(9):2105-16. | ||||
REF 91 | Identification of miR-145 as a key regulator of the pigmentary process.J Invest Dermatol. 2013 Jan;133(1):201-9. | ||||
REF 92 | The microRNA profile of prostate carcinoma obtained by deep sequencing.Mol Cancer Res. 2010 Apr;8(4):529-38. | ||||
REF 93 | MiR-145 functions as a tumor suppressor via regulating angiopoietin-2 in pancreatic cancer cells.Cancer Cell Int. 2016 Aug 25;16(1):65. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.